FDA Advisors: Reject Secondary-Prevention Ezetimibe IndicationFDA Advisors: Reject Secondary-Prevention Ezetimibe Indication
UPDATED // Noting that the secondary-prevention IMPROVE-IT trial's results weren't "clinically substantial," the panel also voiced concerns with hemorrhagic stroke risk and missing study data. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 15, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Dateline City:
KENILWORTH, N.J.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss the results of IMPROVE-IT, an investigational study comparing treatment with VYTORIN® (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes.
Language:
Engl...
Source: Merck.com - Corporate News - December 14, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
FDA panel rejects Merck claim Zetia/Vytorin cut heart risk
(Reuters) - Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday. (Source: Reuters: Health)
Source: Reuters: Health - December 14, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
CardioBreak: FDA Looks at Ezetimibe, VTE Tx in Cancer
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - December 14, 2015 Category: Geriatrics Source Type: news
FDA Takes Another Look at Ezetimibe
(MedPage Today) -- Live blog from Larry Husten (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 14, 2015 Category: American Health Source Type: news
CardioBrief: FDA Panel Poised to Upgrade Ezetimibe Labels?
(MedPage Today) -- Intellectual fireworks, but no real obstacles, expected at advisory meeting (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 11, 2015 Category: Cardiology Source Type: news
Do statins interfere with the flu vaccine?
Statins are powerful, unusual, and, like El Niño and Tom Cruise, not well understood. Statins have a huge upside. They improve survival after heart attacks and lower the risk of recurrent strokes. They are also the only cholesterol-lowering medications that have been clearly shown to reduce heart attacks and deaths in high-risk patients without heart disease. In addition to reducing cholesterol, statins also lower levels of inflammation in the body. Reducing inflammation probably helps statins to prevent heart attack and stroke. However, evidence is emerging that these statin effects may also have a downside, hindering th...
Source: New Harvard Health Information - November 30, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Drugs and Supplements Health Heart Health Vaccines flu vaccine statins Source Type: news
The very high cost of very low cholesterol
You have probably heard about the new cholesterol-lowering drugs Praluent and Repatha, approved by the FDA within the last few weeks. Maybe you’ve even begun taking one of them yourself.
These drugs are miraculous in their ability to lower LDL (low-density lipoprotein cholesterol), the type that leads to heart disease. But this power comes at a great price — literally. Both drugs come at a yearly cost of around $14,600 per year.
The ripple effect of sky-high drug prices
Of course, people taking these drugs may not pay the full cost themselves — that will fall to their insurance company. Exactly how much a person ...
Source: New Harvard Health Information - November 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Drugs and Supplements Health Heart Health Prevention Source Type: news
Personal Health: For Statins, Cholesterol Care May Be Just the Start
Statins are the world’s leading cholesterol-lowering drugs and have other benefits for patients who take them. (Source: NYT)
Source: NYT - November 2, 2015 Category: American Health Authors: JANE E. BRODY Tags: Personal Health Heart Zetia (Drug) Cholesterol Statins (Cholesterol-Lowering Drugs) Live Featured Diet and Nutrition Source Type: news
Personal Health: For Statins, Cholesterol Care May Be Just the Start
Statins are the world’s leading cholesterol-lowering drugs and have other benefits for patients who take them. (Source: NYT Health)
Source: NYT Health - November 2, 2015 Category: Consumer Health News Authors: JANE E. BRODY Tags: Personal Health Heart Zetia (Drug) Cholesterol Statins (Cholesterol-Lowering Drugs) Live Featured Diet and Nutrition Source Type: news
Personal Health: For Statins, Cholesterol Care May Be Just the Start
Statins are the world’s leading cholesterol-lowering drugs and have other benefits for patients who take them. (Source: NYT)
Source: NYT - November 2, 2015 Category: Nutrition Authors: JANE E. BRODY Tags: Personal Health Heart Zetia (Drug) Cholesterol Statins (Cholesterol-Lowering Drugs) Live Featured Diet and Nutrition Source Type: news
NICE recommends ezetimibe for hypercholsterolaemia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2015 Category: Drugs & Pharmacology Source Type: news
NICE updates guidance on hypercholesterolaemia drug
The National Institute for Health and Care Excellence has begun the proces of updating its guidance on the use of ezetimibe (Ezetrol) for primary hypercholesterolaemia by the NHS. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - October 21, 2015 Category: Nursing Source Type: news
Join us for a special webcast: “Rethinking Cholesterol”
If the latest information on health and wellness is important to you, you will not want to miss a special live-streamed webcast, “Rethinking Cholesterol,” which will be aired on Thursday, September 24, from 12:30pm to 1:30pm Eastern time. The webcast, which is free to all viewers, is co-sponsored by Reuters, Harvard Health Publications, the Harvard T.H. Chan School of Public Health, and Harvard Medical School.
Recent science has brought new insights into the importance of controlling cholesterol for maintaining cardiovascular health. LDL (low-density lipoprotein) cholesterol is a potent risk factor for heart and blood ...
Source: New Harvard Health Information - September 22, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Health cholesterol high cholesterol Lowering Cholesterol Source Type: news
Impact of Dual Lipid-Lowering on Coronary PlaqueImpact of Dual Lipid-Lowering on Coronary Plaque
Find out how ezetimibe and atorvastatin combined impact coronary atherosclerosis in patients undergoing PCI. Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
